CXCL10 and hematopoietic and lymphoid cell neoplasm: Conversely, data from all hematological cancer cells showed significant (p < 0.005) differences in levels of CXCL9 and MICA expression only after guadecitabine and DAC treatment vs. untreated cells; while significant (p < 0.05) differences in levels of CXCL10 and MICB expression were observed only after AZA treatment, compared to untreated cells (Supplementary Tables 19–22).